Table 1 Clinical and demographic characteristics
Characteristics | N = 145 |
|---|---|
Male gender | |
 n (%) | 129 (89.0) |
Age, years | |
 Mean (SD) | 37.8 (4.2) |
Previous IVDU | |
 N (%) | 129 (89.0) |
Education | |
 University, n (%) | 64 (44.1) |
 Secondary, n (%) | 79 (54.5) |
 Primary, n (%) | 2 (1.4) |
Marital status | |
 Married, n (%) | 85 (58.6) |
 Widow/widower/divorce, n (%) | 22 (15.2) |
 Not married, n (%) | 38 (26.2) |
Employment status | |
 Regular employment, n (%) | 67 (46.2) |
 Non-regular employment, n (%) | 56 (38.6) |
 Not working, n (%) | 22 (15.2) |
Religion | |
 Moslem, n (%) | 114 (78.6) |
 Christian | 29 (20.0) |
 Buddhist | 2 (1.4) |
Alcohol use | |
 Active, n (%) | 25 (17.2) |
 Past, n (%) | 111 (76.6) |
 Never, n (%) | 9 (6.2) |
Tobacco use | |
 Active smoker, n (%) | 73 (50.4) |
 Past smoker, n (%) | 66 (45.5) |
 Never smoke, n (%) | 6 (4.1) |
BMI | |
 Mean (SD) | 22.3 (3.5) |
Hemoglobin, g/dL | |
 Mean (SD) | 14.9 (4.3) |
Recent CD4+ T cell count, cells/µL | |
 Median (IQR) | 485 (392–675) |
ART duration, years | |
 Median (IQR) | 9 (4–12) |
ART regimen | |
 NNRTI-based, n (%) | 126 (86.9) |
 PI-based, n (%) | 19 (13.1) |
HBV co-infection | |
 n (%) | 6 (4.1) |
HCV treatment history | |
 Treatment naïve, n (%) | 132 (91) |
 Interferon failure, n (%) | 13 (9) |
Fibrosis stage | |
 F0–F1, n (%) | 86 (59.3) |
 F2–F3, n (%) | 30 (20.7) |
 F4, n (%) | 29 (20) |
HCV-RNA, IU/mL | |
 > 800,000, n (%) | 110 (75.9) |
 < 800,000, n (%) | 35 (24.1) |
 Mean (SD), log10 | 6.22 (0.83) |
HCV genotype | |
 1, n (%) | 23 (15.8) |
 2, n (%) | 4 (2.8) |
 3, n (%) | 3 (2.1) |
 4, n (%) | 3 (2.1) |
 Not available, n (%) | 112 (77.2) |
DAA combination | |
 SOF + DAC60, n (%) | 30 (20.7) |
 SOF + DAC90, n (%) | 115 (79.3) |
Duration of DAA treatment | |
 12 weeks, n (%) | 116 (80) |
 24 weeks, n (%) | 29 (20) |
DAA treatment response | |
 SVR12, n (%) | 138 (95.5) |
 Non-responder, n (%) | 7 (4.5) |